Moderna's COVID vaccine gets full US approval for at-risk children aged 6 months and older
Tired of too many ads? go ad free now
The move marks a shift in federal policy under Health and Human Services Secretary Robert F. Kennedy Jr., who has led a controversial effort to scale back universal access to pediatric COVID shots.
The Food and Drug Administration's decision, announced Thursday, means that healthy children in this age group will no longer have routine access to the vaccine unless it is prescribed off-label. Moderna's shares rose more than 4% in early trading in New York following the announcement.
Under emergency use authorization during the pandemic, COVID-19 vaccines from Moderna and Pfizer were made widely available to all children. But Kennedy, a longtime vaccine skeptic, has reversed course. In 2021, he petitioned the FDA to revoke temporary approval for children's vaccines, citing low risk of severe illness in healthy children. Now, the vaccine's full approval ensures it remains available for high-risk kids, but also restricts broader access.
What are the risks of SPIKEVAX?
For most people, getting the SPIKEVAX COVID-19 vaccine is safe and simple. But like any vaccine, there are some rare risks you should know about.
There's a very small chance of having a serious allergic reaction, usually within a few minutes to an hour after the shot. That's why your doctor or nurse may ask you or your child to wait for a short time after getting vaccinated—just to be safe.
As per the official website of Moderna, signs of a serious allergic reaction may include:
Difficulty breathing
Swelling of the face or throat
A fast or racing heartbeat
A rash all over the body
Dizziness or weakness
In rare cases, some people—mostly boys and young men between 12 and 24 years old—have developed myocarditis (inflammation of the heart muscle) or pericarditis (inflammation of the lining around the heart) after getting an mRNA COVID-19 vaccine like SPIKEVAX.
Tired of too many ads? go ad free now
If you or your child experiences any of the following symptoms within two weeks of the vaccine, it's important to see a doctor right away:
Chest pain
Shortness of breath
A fast, fluttering, or pounding heartbeat
In children, signs to watch for can include chest pain, shortness of breath, pounding heartbeat, fainting, being unusually tired or irritable, poor feeding, stomach pain, vomiting, or cool, pale skin.
What are the possible side effects of SPIKEVAX?
Common side effects around the injection site: pain or tenderness, redness, swelling or firmness, and swollen lymph nodes in the same arm or sometimes in the groin
General side effects: feeling tired or sleepy, headache, muscle or joint pain, chills or fever, nausea or vomiting, rash, irritability or crying (especially in young children) and loss of appetite.
In some cases, people have also reported fainting or febrile seizures (seizures caused by a fever). While these are less common, it's helpful to be aware of them.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Indian Express
an hour ago
- Indian Express
GMCH-32: Newly constructed block to be inaugurated on Aug 8, to decongest gynaecology dept
The newly constructed 283-bed Emergency-cum-Trauma Block at GMCH-32 is all set to be inaugurated on August 8, to coincide with the 11th convocation, promising to reduce overload on the existing emergency units in the city, improve patient care and ensure better utilisation of resources. In the hospital's history, the A Block, where 24-hour emergency services are provided to patients, was the first to become functional, and since 1996, there has been no renovation of this block. 'With the new state-of-the-art trauma block ready for patients, the first step will be to renovate the area, with the engineering and fire safety departments already in action to ensure the latest facilities, amenities and safety. Once this is complete, we will start the process of decongesting our gynaecology department, which also comprises the labour room, and witnesses patients from across the region, including the large migrant population that we have. We will be utilising this space for the expansion of the department, and also add more beds to ease rush. We are making efforts to provide more speciality and super-speciality services. The process of space creation is a dynamic one,' said Prof A K Attri, Director-Principal, GMCH-32. The gynaecology department of the hospital has 100 beds, with 10 beds added way back in 2017. The number of patients in the gynaecology department is very high, and despite the increase in beds, there are not enough beds for pregnant women. More than 5,000 women deliver in GMCH every year, and when the number of cases is higher, two women have to be adjusted on one bed, with the occupancy rate almost 200 per cent. The hospital receives delivery cases from Chandigarh, Punjab, Haryana, Himachal, Uttarakhand, UP, and despite the shortage of beds, the effort is to provide treatment. As per doctors, the gynaecology department of GMCH-32 has the highest number of deliveries, followed by GMSH-16 and then PGI. Both PGI and GMCH-32 will have exclusive Mother and Child Centres, with work on the project of GMCH-32 having started in 2018, but was delayed due to COVID and has now restarted. With a budget of about Rs 73 crore, the centre, which will be open in about two years, will have two basements and four floors and have a facility of 251 beds, with the latest facilities and services under one roof. Dr Attri said it will decrease infant and mother mortality rate. PGI's Advanced Mother and Child Care Centre, where work is in full swing and may be inaugurated at the end of this year, will be equipped with the latest technologies and offer world-class facilities in both maternal and neonatal care. A human milk bank, advanced infertility treatment, robotic surgery, critical care obstetrics, high-risk maternity unit, foetal medicine unit, pre-implantation genetic diagnosis, prenatal diagnosis, and reproductive endocrinology unit will be part of the centre. Here, there will be a modern developmentally supportive and family-centred level IV NICU designed as per current International NICU design specifications, a family-centred Kangaroo Mother Care ward, and a comprehensive high-risk follow-up programme. A long-needed facility, the Advanced Paediatric Centre at GMSH-16 was inaugurated last year. The 32-bedded facility offers state-of-the-art specialised care, featuring a 12-bedded hybrid ICU unit comprising ventilator beds and high-dependency unit beds. The centre includes 20 oxygen-supported beds and features ECG, echocardiography, and ultrasonography, all under one roof, so that parents don't have to go anywhere for these tests and their children receive the best care. There are 24-hour services like blood transfusion, sample collection, nebulisation etc, for critical patients, and this advanced centre has eased the burden on PGI.
Time of India
an hour ago
- Time of India
US Health Secretary Kennedy to oust members of US preventive task force
Bengaluru: Health Secretary Robert F. Kennedy Jr. is planning to remove all the members of an advisory panel that determines what cancer screenings and other preventive health measures insurers must cover, the Wall Street Journal reported on Friday, citing people familiar with the matter. Kennedy plans to dismiss all 16 panel members of the U.S. Preventive Services Task Force , according to the WSJ report. This is the latest in a series of far-reaching actions by Kennedy, a long-time vaccine skeptic, to reshape U.S. regulation of vaccines, food and medicine. In June, Kennedy dismissed all 17 members of the Advisory Committee on Immunization Practices (ACIP), replacing them with eight new members including known vaccine skeptics. The USPSTF includes medical experts serving four-year terms on a volunteer basis and has a major role in choosing what services will be covered under the 2010 Affordable Care Act , also known as Obamacare. The U.S. Supreme Court in June upheld the constitution of the task force and ruled in favor of its recommendation to cover preventive care such as cancer screenings and HIV prevention medication at no cost to patients. Its members are selected by the U.S. Secretary of Health and Human Services without Senate confirmation.
Time of India
8 hours ago
- Time of India
AIOCD demands strict action against illegal e-pharmacies; raises alarm over inaction by SLAs
The All-India Organisation of Chemists and Druggists ( AIOCD ), representing over 12.40 lakh chemists across India, has expressed grave concern over the illegal and unregulated operation of online pharmacy platforms, which allegedly continue to sell medicines in violation of the Drugs & Cosmetics Act, 1940, posing a serious threat to public health . Accoridng to a statement from AIOCD, JS Shinde, President, Rajiv Singhal, General Secretary, informed that in a formal communication addressed to the Minister of State for Health and Family Welfare, Anupriya Patel, AIOCD has highlighted the continued inaction by State Licensing Authorities (SLAs), despite repeated complaints being forwarded to them by the Central Drugs Standard Control Organisation ( CDSCO ). Explore courses from Top Institutes in Please select course: Select a Course Category Degree PGDM Operations Management MCA Data Science CXO healthcare MBA Technology Management Data Science Project Management Healthcare Cybersecurity Finance Data Analytics Leadership Design Thinking Others Artificial Intelligence others Digital Marketing Product Management Public Policy Skills you'll gain: Data-Driven Decision-Making Strategic Leadership and Transformation Global Business Acumen Comprehensive Business Expertise Duration: 2 Years University of Western Australia UWA Global MBA Starts on Jun 28, 2024 Get Details While the Minister's reply in the Rajya Sabha on 22nd July 2025 stated that complaints regarding unauthorised sale of medicines are referred to SLAs, however, AIOCD has informed that no visible or effective action has been taken by any SLA across the country. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Play War Thunder now for free War Thunder Play Now Undo To escalate this matter further, a high-level delegation of AIOCD met with the Drug Controller General of India (DCGI), Dr Rajeev Raghuvanshi, on July 21, and urged him to take the following urgent actions: Immediate crackdown on all illegal e-pharmacies operating without any valid license or oversight, including the Quick Commerce Players; Withdrawal of GSR 220(E), which was issued during the COVID-19 epidemic but is now being misused by these platforms to justify unlawful activities, and Withdrawal of GSR 817(E), the draft regulation issued in August 2018, which has remained in draft form for over eight years, enabling misuse due to lack of legal clarity, according to the statement. AIOCD has repeatedly submitted that GSR 817(E) is outdated and has failed to address the ground realities of digital drug distribution. Live Events JS Shinde, President, Rajiv Singhal, General Secretary, AIOCD, highlighted that the loosely drafted definition of 'Manufacturer' is the root cause of the issue and emphasised the need for a holistic and comprehensive approach involving all concerned departments, the statement said. AIOCD also expressed its readiness to provide suitable amendments to the Act, Rules, and relevant orders. AIOCD reiterated that medicines are not ordinary consumer goods, and their sale and distribution must not be left to automated platforms or unauthorized logistics chains. Continued inaction will lead to a public health disaster of irreversible scale. According to the statement, AIOCD demanded immediate withdrawal of GSR 817(E) and GSR 220(E) to prevent further legal misuse; Centralized enforcement action by CDSCO against all illegal online pharmacies; Action of all illegal E pharmacies on government directives must be initiated immediately by State SLA's . AIOCD appeals to the Ministry of Health and Family Welfare to take urgent action in the interest of safeguarding public health and restoring trust in India's pharmaceutical regulatory system, the statement added.
